Resverlogix Commences Phase 3 Clinical Trial BETonMACE With Apabetalone
Calgary, Alberta (ots/PRNewswire) - Apabetalone will be evaluated in a Phase 3 clinical trial in high-risk coronary artery disease and type 2 diabetes mellitus patients Resverlogix Corp. (the "Corporation") today announced the commencement of a Phase 3 clinical trial called 'BETonMACE' with lead drug apabetalone (RVX-208) in high-risk patients with coronary artery ...